References
- World Health Organization. Cancer. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer [last accessed 28 Apr 2019]
- American Society of Clinical Oncology. Breast cancer statistics. Available from: https://www.cancer.net/cancer-types/breast-cancer/statistics/2015 [last accessed 28 Apr 2019]
- Cancer research UK. Breast cancer statistics. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer#heading-Three [last accessed 28 Apr 2019]
- Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001;7:535–43
- MacMillan Cancer Support. Guidance on long-term consequences of treatment for gynaecological cancer. Available from: http://be.macmillan.org.uk/Downloads/CancerInformation/ResourcesForHSCP/InformationResources/MAC14942GYNAEGUIDEWEB.pdf [last accessed 28 Apr 2019]
- Walshe JM, Denduluri N, Swain SM. Amenorrhoea in premenopausal women after adjuvant chemotherapy for breast cancer. JCO 2006;24:5769–79
- Zhao J, Liu J, Chen K. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat 2014;145:113–28
- Park J, Kim T-H, Lee H-H, Chung S-H, Lee D. Gynecologic complication of chronic graft-versus-host disease: vaginal obstruction. Obstet Gynecol Sci 2013;56:277–80
- Ciavattini A, Clemente N. Female genital tract chronic graft-versus-host disease: review of the literature. Anticancer Res 2015;35:13–7
- Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87–94
- Sturdee DW, Panay N, International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509–22
- Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Climacteric 2014;17:557–63
- Nappi RE, Palacios S, Bruyniks N, Particco M, Panay N, EVES Study investigators. The burden of vulvovaginal atrophy on women’s daily living: implications on quality of life from a face-to-face real-life survey. Menopause 2019;26:485–91
- Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturiser composition? Climacteric 2016;19:151–61
- Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 2003;45:29–38
- Hunter MM, Nakagawa S, Van Den Eeden SK, Kuppermann M, Huang AJ. Predictors of impact of vaginal symptoms in postmenopausal women. Menopause 2016;23:40–6
- RAND Health Care. 36-Item Short Form Survey (SF-36). Available from: https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form.html [last accessed 28 Apr 2019]
- Euro-Qol Research Foundation. EQ-5D. Available from: https://euroqol.org/eq-5d-instruments/eq-5d-3l-about/ [last accessed 28 Apr 2019]
- Female Sexual Function Index. Available from: www.fsfiquestionnaire.com [last accessed 28 Apr 2019]
- Baser RE, Li Y, Carter K. Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors. Cancer 2012;118:4606–18
- Shifren JL, Zincavage R, Cho EL, et al. Women’s experience of vulvovaginal symptoms associated with the menopause. Menopause 2019;26:341–9
- Panay N, Palacios S, Bruyniks N, Particco M, Nappi RE. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas 2019;124:55–61
- Biglia N, Bounous VE, D'Alonzo M, et al. Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists. Clin Breast Cancer 2017;17:611–17
- National Institute for Health and Care Excellence. Menopause: diagnosis and management. NICE guideline (NG 23). Published: November 2015. Available from: https://www.nice.org.uk/guidance/ng23 [last accessed 28 Apr 2019]
- National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management. NICE guideline (NG101) Published: July 2018. Available from: https://www.nice.org.uk/guidance/ng101 [last accessed 28 Apr 2019]
- Marsden J, Marsh M, Rigg A, British Menopause Society. British Menopause Society consensus statement on the management of estrogen deficiency symptoms, arthralgia and menopause diagnosis in women treated for early breast cancer. Post Reprod Health 2019;25:21–32
- Management of symptomatic vulvovaginal atrophy: 2013 Position statement of the North American Menopause Society. Menopause 2013;20:888–902
- Kingsberg SA, Larkin L, Krychman M, Parish SJ, Bernick B, Mirkin S. WISDOM survey: attitudes and behaviours of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause 2019;26:124–31
- National Cancer Institute. Menopausal hormone therapy. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/mht-fact-sheet [last accessed 28 Apr 2019]
- Mitchell C, Reed S, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Intern Med 2018;178:681–90
- Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480–6
- Bruyniks N, Biglia N, Palacios S, Mueck AO. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric 2017;20:195–204
- Salvatore S, Franca K, Lottie T, et al. Early regenerative modifications of human postmenopausal atrophic vaginal mucosa following fractional CO2 laser treatment. Open Access Maced J Med Sci 2018;6:6–14
- Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric 2014;17:363–9
- Preti M, Vieira-Baptista P, Digesu GA, et al. The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: an ICS/ISSVD best practice consensus document. Neurourol Urodyn 2019;38:1009–23
- US Food and Drug Administration. FDA warns against use of energy-based devices to perform vaginal 'rejuvenation' or vaginal cosmetic procedures: FDA safety communication. Available from: https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-use-energy-based-devices-perform-vaginal-rejuvenation-or-vaginal-cosmetic [last accessed 28 Apr 2019]
- Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric 2010;13:219–27
- Le Ray I, Dell’Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat 2012;135:603–9
- Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003;6:45–52
- Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev 2018;(5):CD008830
- Saeaib N, Peeyananjarassri K, Liabsuetrakul T, Buhachat R, Myriokefalitaki E. Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database Syst Rev 2017;(2):CD012559
- Hopkins ML, Fung MF, Le T, Shorr R. Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecol Oncol 2004;92:827–32
- Li D, Ding CY, Qiu LH. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol Oncol 2015;139:355–62
- Bell RJ, Rizvi F, Islam RM, Davis SR. A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy. Menopause 2018;25:704–9
- Davis SR, Robinson PJ, Jane F, White S, White M, Bell RJ. Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab 2018;103:4146–54
- Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923–31
- Sauer U, Talaulikar V, Davies MC. Efficacy of intravaginal dehydroepiandrosterone (DHEA) for symptomatic women in the peri- or postmenopausal phase. Maturitas 2018;116:79–82
- Santen RJ, Stuenkel CA, Davis SR, Pinkerton JV, Gompel A, Lumsden MA. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab 2017;102:3647–61
- Martel C, Labrie F, Archer DF, et al. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. J Steroid Biochem Mol Biol 2016;159:142–53